Amarin Corporation PLC (NASDAQ:AMRN) – Equities research analysts at Jefferies Group dropped their FY2018 earnings estimates for Amarin Corporation PLC in a research report issued on Thursday, Zacks Investment Research reports. Jefferies Group analyst M. Andrews now anticipates that the biopharmaceutical company will post earnings per share of ($0.09) for the year, down from their previous estimate of ($0.07). Jefferies Group has a “Buy” rating on the stock.
Other equities analysts have also recently issued reports about the stock. BidaskClub cut shares of Amarin Corporation PLC from a “hold” rating to a “sell” rating in a research note on Friday, August 11th. ValuEngine cut shares of Amarin Corporation PLC from a “hold” rating to a “sell” rating in a research note on Thursday. Cantor Fitzgerald set a $10.00 target price on shares of Amarin Corporation PLC and gave the stock a “buy” rating in a research report on Monday. HC Wainwright restated a “buy” rating and set a $10.00 target price on shares of Amarin Corporation PLC in a research report on Thursday, August 3rd. Finally, Zacks Investment Research upgraded shares of Amarin Corporation PLC from a “hold” rating to a “buy” rating and set a $4.00 target price on the stock in a research report on Tuesday, October 3rd. Two research analysts have rated the stock with a sell rating, one has given a hold rating and three have given a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and a consensus target price of $7.75.
ILLEGAL ACTIVITY WARNING: “Amarin Corporation PLC to Post FY2018 Earnings of ($0.09) Per Share, Jefferies Group Forecasts (NASDAQ:AMRN)” was posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this news story on another domain, it was copied illegally and reposted in violation of US and international copyright legislation. The original version of this news story can be viewed at https://www.dispatchtribunal.com/2017/11/17/jefferies-group-brokers-decrease-earnings-estimates-for-amarin-corporation-plc-amrn.html.
Shares of Amarin Corporation PLC (NASDAQ AMRN) traded down $0.18 on Monday, reaching $3.24. 2,110,505 shares of the company’s stock traded hands, compared to its average volume of 1,752,364. The company has a debt-to-equity ratio of -1.48, a quick ratio of 1.32 and a current ratio of 1.63. Amarin Corporation PLC has a 12 month low of $2.81 and a 12 month high of $4.47.
Amarin Corporation PLC (NASDAQ:AMRN) last announced its earnings results on Wednesday, November 1st. The biopharmaceutical company reported ($0.04) EPS for the quarter, beating analysts’ consensus estimates of ($0.05) by $0.01. The business had revenue of $47.10 million during the quarter, compared to analyst estimates of $45.85 million. The business’s revenue was up 45.4% compared to the same quarter last year. During the same period in the previous year, the firm earned ($0.08) earnings per share.
Several institutional investors have recently added to or reduced their stakes in AMRN. Wells Fargo & Company MN boosted its position in shares of Amarin Corporation PLC by 4.8% in the 1st quarter. Wells Fargo & Company MN now owns 32,801 shares of the biopharmaceutical company’s stock worth $105,000 after buying an additional 1,500 shares in the last quarter. JPMorgan Chase & Co. lifted its holdings in Amarin Corporation PLC by 27.1% in the 1st quarter. JPMorgan Chase & Co. now owns 35,590 shares of the biopharmaceutical company’s stock valued at $114,000 after purchasing an additional 7,580 shares in the last quarter. Westside Investment Management Inc. lifted its holdings in Amarin Corporation PLC by 1.1% in the 2nd quarter. Westside Investment Management Inc. now owns 27,350 shares of the biopharmaceutical company’s stock valued at $114,000 after purchasing an additional 300 shares in the last quarter. Perkins Capital Management Inc. lifted its holdings in Amarin Corporation PLC by 20.3% in the 2nd quarter. Perkins Capital Management Inc. now owns 41,500 shares of the biopharmaceutical company’s stock valued at $167,000 after purchasing an additional 7,000 shares in the last quarter. Finally, Cubist Systematic Strategies LLC purchased a new position in Amarin Corporation PLC in the 3rd quarter valued at about $226,000. Institutional investors and hedge funds own 37.67% of the company’s stock.
In related news, insider Steven B. Ketchum sold 63,479 shares of the business’s stock in a transaction dated Thursday, October 5th. The shares were sold at an average price of $3.48, for a total value of $220,906.92. The transaction was disclosed in a document filed with the SEC, which is available through this link. 3.72% of the stock is owned by insiders.
About Amarin Corporation PLC
Amarin Corporation plc is a biopharmaceutical company with operations in lipid science focused on the commercialization and development of therapeutics for cardiovascular health. The Company operates through the development and commercialization of Vascepa segment. The Company’s lead product, Vascepa (icosapent ethyl) capsule, is approved by the United States Food and Drug Administration (FDA) for use as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia.
Get a free copy of the Zacks research report on Amarin Corporation PLC (AMRN)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Amarin Corporation PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amarin Corporation PLC and related companies with MarketBeat.com's FREE daily email newsletter.